Home » Topics » BioWorld Science

BioWorld Science
RSS

Genmab initiates phase I/IIa safety study of GEN-1046 in malignant solid tumors

May 27, 2019

Phase III study of Lyrica in PGTC seizures fails to meet primary endpoint

May 27, 2019

PCI Biotech begins pivotal RELEASE study of fimaChem in inoperable bile duct cancer

May 27, 2019

Sensorion signs hearing loss research partnership framework agreement with Institut Pasteur

May 27, 2019

Alpine Immune Sciences divulges new fusion proteins

May 27, 2019

Nanjing CART Medical Technologies discloses CAR T cells for hematologic cancer

May 27, 2019

Zealand Pharma describes amylin and/or calcitonin receptor agonists

May 27, 2019

FDA approves Piqray for HR+/HER2-, PIK3CA-mutated advanced breast cancer

May 27, 2019

ORIC Pharmaceuticals presents CD73 inhibitors

May 27, 2019

Aclaris Therapeutics patents JAK1 and JAK3 inhibitors

May 27, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...